A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Ruth M. Farrell, MD, MA, Marsha Michie, PhD, Christopher T. Scott, PhD, Rebecca Flyckt, MD, and Mary LaPlante, MD
One reason for neglect of women’s health as patients and subjects has been restrictions on uterine transfer of modified human embryos, a boundary that has now been crossed.
AMA J Ethics. 2019;21(12):E1071-1078. doi:
10.1001/amajethics.2019.1071.
Weyinshet Gossa, MD, MPH and Michael D. Fetters, MD, MPH, MA
Cervical cancer has become rare in high-income countries but is a leading cause of mortality among women in low- and middle-income countries. This inequity is an epidemiological tragedy.
AMA J Ethics. 2020;22(2):E126-134. doi:
10.1001/amajethics.2020.126.
Madeleine (Maddy) Kane, Rachel Bervell, MD, MS, Angela Y. Zhang, MD, and Jennifer Tsai, MD, MEd
Algorithms use race as an epidemiological shorthand, but clinically influential historical, social, and cultural determinants of health are still sources of variability.
AMA J Ethics. 2022;24(8):E720-728. doi:
10.1001/amajethics.2022.720.
Theodore E. Schall, PhD, MSW, MBE, Kaitlyn Jaffe, PhD, and Jacob D. Moses, PhD
Clinicians should know how randomized controlled trials can and cannot contribute to advancing health equity for transgender and gender diverse people.
AMA J Ethics. 2024;26(9):E684-689. doi:
10.1001/amajethics.2024.684.